Log in or register to see all Alerts
New HTA Decisions in Germany
March 2021
Drug name
TALTZ® (ixekizumab)
Lilly Deutschland GmbH
Decision date
Therapeutic area
Skin conditions
Therapeutic sub area
G-BA decision date
Orphan Drug?
No additional benefit
Children and adolescents from 6 years of age with a body weight of at least 25kg who have moderate to severe plaque psoriasis and are eligible for systemic therapy. Main comparator: Adalimumab or etanercept or ustekinumab.
Decision Detail
Main studies: IXORA-S and IXORA-PEDS. Main driver of decision: Due to a lack of studies involving children and adolescents with a duration of at least 24 weeks (during IXORA-PEDS data comparing the drug and comparator were only available for 12 weeks), the company also utilised data from the adult study IXORA-S. However, the company's approach to information procurement, processing of results and the transfer of the additional benefit was deemed incomplete and inconsistent, with IQWiG concluding that there was no interpretable data available.
IQWiG concluded that there was insufficient evidence presented to assess added benefit.